UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K
AMENDMENT NO. 1

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): May 19, 2008 (May 9, 2008)

DATE OF ORIGINAL REPORT: May 15, 2008 (May 9, 2008)

NT HoldingCorp.
- --------------------------------------------------------------------------------
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)

NEVADA
- --------------------------------------------------------------------------------
(STATE OR OTHER JURISDICTION OF INCORPORATION)

000-15303 73-1215433
- --------------------------------------------------------------------------------
(COMMISSION FILE NUMBER) (IRS EMPLOYER IDENTIFICATION NO.)

150 Research Drive, Hampton, VA 23666
- --------------------------------------------------------------------------------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)

757-766-6100
- --------------------------------------------------------------------------------
Registrant's telephone number, including area code:

N/A
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions

[ ] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

ITEM 1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT

Effective May 5, 2008, NT Holding Corp. (the "Company") entered into a
Reorganization and Stock Purchase Agreement (the "Acquisition") with Health
Source Technologies, Inc. ("HSTI") to acquire 100% of the issued and outstanding
equity of HSTI in exchange for a majority interest in the Company. The
transaction closed on May 9, 2008.

In conjunction with the Acquisition, effective May 9, 2008, the Company entered
into an Assignment and Assumption Agreement (the "Assignment") with Rider Point
International ("RPI") to assign 100% of the Company's assets held before the
Acquisition to RPI in exchange for the assumption of 100% of the Company's
liabilities incurred before the Acquisition.

ITEM 2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS

Effective May 9, 2008, the Company acquired 100% of the outstanding equity of
Health Source Technologies, Inc. ("HSTI") from the shareholders of HSTI, in
consideration for 66,000,000 shares of the Company's common stock, representing
a majority interest and 1,000,000 shares of Series A Preferred Stock, each share
convertible into 405 shares of common stock. Upon completion of the acquisition
and appropriate notice to Shareholders under a 14C Information Statement, the
Company intends to complete a 1 for 25 reverse stock split. A more detailed
description of HSTI follows below. In conjunction with the Acquisition, the
Company assigned 100% of its assets and 100% of its liabilities to Rider Point
International through the Assignment simultaneously with the Acquisition.

DESCRIPTION OF BUSINESS OF HSTI

CORPORATE HISTORY

Health Source Technologies, Inc. ("HSTI") was incorporated in Nevada on August
6, 2007. HSTI has not been in bankruptcy, receivership, or any similar
proceeding, and, has not defaulted on the terms of any note, loan, lease, or
other indebtedness or financing arrangement requiring HSTI to make any material
payments. Other than the Acquisition, HSTI has not been a party to any material
reclassification, merger, consolidation, or purchase or sale of a significant
amount of assets not in the ordinary course of business.

COMPANY OVERVIEW

Health Source Technologies, Inc. is a development stage biopharmaceutical
company that acquires and develops innovative products for the treatment of
cancer. We have focused on in-licensing drug candidates that are undergoing or
have already completed initial clinical testing for the treatment of cancer, and
then developing those drug candidates for commercial use.

We entered into a letter of intent ("LOI") with Joe Brown for the rights to one
clinical stage drug candidate:

- - Salicinium - Salicinium is an oral and parental active inhibitor of NAD+
e.c. 1.2.1.28 fermenting enzyme dynamics. Clinical studies demonstrate that
Salicinium alters malignant cell fermentation dynamics, blocks cell
division (mitosis) and causes fermenting (cancer) cells' loss of ability to
withstand the innate immune reactions.

The letter of intent has expired, but we are currently in negotiations to extend
the terms of the LOI, and intend to complete a definitive licensing agreement
within 30 days of the extension. We do not anticipate any issues with this
extension.

We were originally incorporated under Nevada law on August 6, 2007 under the
name Health Source Technologies, Inc. Over the course of this year, we intend
to retain a Chief Executive Officer and continue to build our board of directors
with new experienced additional directors with the intention of beginning our
FDA testing of our clinical stage drug. We continue to search for additional
cancer applications for our product candidate.

OUR STRATEGY

We intend to focus on in-licensing and further developing drug candidates that
are undergoing or have already completed initial clinical testing for the
treatment of cancer. Although the cost of licensing drug candidates for which
the initial clinical testing has been completed may be significantly higher than
those for which clinical testing has not been completed, we believe there is
significantly less risk associated with our investment and continued development
of clinical stage drugs due to the fact that we are able to obtain an initial
indication of the drug's safety and efficacy before we decide to invest our
capital in the drug's development.

We will consider potential drug acquisitions through a number of sources,
including solicitations from potential sellers of such drugs and through
searches completed by both our directors and by independent consulting firms.
In considering potential acquisitions, we will complete an evaluation of the
scientific and medical viability of the drug. Depending on the drug, this
evaluation would be completed by us internally if any of the members of our team
have specific experience with the related technology or by third party
consultants with specific experience with the related technology. In addition
to scientific and medical viability factors, we will also consider the drug from
a market perspective, considering not only the prospective expense of
development and commercialization of the drug, but also the economic potential
of the drug on such market if successfully developed. Internal evaluation, when
undertaken, will also be completed by a Scientific Advisory Board which we
intend to form, whose members assist management in the assessment of research,
development and commercial programs of biotechnology or pharmaceutical companies
that HSTI may consider acquiring, and provide advice and guidance with respect
to the research and commercial development plans of our product portfolio. We
will not enter into any licensing transaction unless our board of directors has
first approved the transaction. Its decision will depend on several factors,
including the scientific merits of the technology, the costs of the transaction
and other economic terms of the proposed license, the amount of capital required
to develop the technology, and the economic potential of the drug candidate
should it be commercialized.

Currently, we do not follow any policy or formula as to our acquisition of
product candidates, other than seeking drugs for which pre-clinical or clinical
testing has commenced. To date, we

have entered into a letter of intent to acquire one product candidate. We will
continue to consider potential acquisitions based on the consideration of the
factors identified above.

As we move our product candidates through development toward regulatory
approval, we will evaluate several options for each product candidate's
commercialization strategy. These options include building our own internal
sales force, entering into a joint marketing partnership with another
pharmaceutical or biotechnology company whereby we jointly sell and market the
product, and out-licensing our product whereby another pharmaceutical or
biotechnology company sells and markets our product and pays us a royalty on
sales. Our decision will be made separately for each product and will be based
on a number of factors including capital necessary to execute on each option,
size of the market that needs to be addressed and terms of potential offers from
other pharmaceutical and biotech companies. It is too early for us to know which
of these options we will pursue for our product candidates, assuming their
successful development.

OUR PRODUCT CANDIDATE

Salicinium has the distinct advantage of having been studied in 170 human stage
IV (terminal) cancer patients in Reno, Nevada. Of those patients, 43 were
diagnosed with stage IV breast cancer. The results after 2 years show 79%
efficacy, or that 34 of the patients survived.

The study was conducted by Dr. James Forsythe who is both a Medical Doctor and a
Homeopathic Doctor. Dr. Forsythe has been a clinical oncologist for over 30
years and has done many clinical studies, but has stated that he has never seen
a drug candidate with clinical results like this one.

The study was conducted under Homeopathic guidelines governed by the state of
Nevada.

BREAST CANCER STATISTICS

According to The American Cancer Society, breast cancer is the most common
cancer among women in the United States, other than skin cancer. It is the
second leading cause of cancer death in women, after lung cancer.

About 178,480 women in the United States will be found to have invasive breast
cancer in 2007. About 40,460 women will die from the disease in 2008. Right
now there are about two and a half million breast cancer survivors in the United
States.

The chance of a woman having invasive breast cancer some time during her life is
about 1 in 8. The chance of dying from breast cancer is about 1 in 35. Breast
cancer death rates are going down. Management believes that this is probably
the result of finding the cancer earlier and improvements in treatment.

TYPES OF BREAST CANCERS

There are many types of breast cancer, though some of them are very rare.
Sometimes a breast tumor can be a combination of these types and to have a
mixture of "invasive" and "in situ" cancer.

DUCTAL CARCINOMA IN SITU (DCIS): This is the most common type of non-invasive
breast cancer. DCIS means that the cancer is only in the ducts. It has not
spread through the walls of the ducts into the tissue of the breast. Nearly all
women with cancer at this stage can be cured. Often the best way to find DCIS
early is with a mammogram.

LOBULAR CARCINOMA IN SITU (LCIS): This condition begins in the milk-making
glands but does not go through the wall of the lobules. Although not a true
cancer, having LCIS increases a woman's risk of getting cancer later. For this
reason, it's important that women with LCIS follow the screening guidelines for
breast cancer (these are discussed later in this document).

INVASIVE (INFILTRATING) DUCTAL CARCINOMA (IDC): This is the most common breast
cancer. It starts in a milk passage or duct, breaks through the wall of the
duct, and invades the tissue of the breast. From there it can spread to other
parts of the body. It accounts for about 8 out of 10 invasive breast cancers.

INVASIVE (INFILTRATING) LOBULAR CARCINOMA (ILC): This cancer starts in the milk
glands or lobules. It can spread to other parts of the body. About 1 out of 10
invasive breast cancers are of this type.

INFLAMMATORY BREAST CANCER (IBC): This uncommon type of invasive breast cancer
accounts for about 1% to 3% of all breast cancers. Usually there is no single
lump or tumor. Instead, inflammatory breast cancer (IBC) makes the skin of the
breast look red and feel warm. It also gives the skin a thick, pitted
appearance that looks a lot like an orange peel. Doctors now know that these
changes are not caused by inflammation or infection, but by cancer cells
blocking lymph vessels in the skin. The breast may become larger, firmer,
tender, or itchy. IBC is often mistaken for an infection in its early stages.
Because there is no defined lump, it may not appear on a mammogram, which may
make it even harder to catch it early. It usually has a higher chance of
spreading and a worse outlook than invasive ductal or lobular cancer.

GOVERNMENT REGULATION AND PRODUCT APPROVAL

The FDA and comparable regulatory agencies in state and local jurisdictions and
in foreign countries impose substantial requirements upon the testing
(preclinical and clinical), manufacturing, labeling, storage, recordkeeping,
advertising, promotion, import, export, marketing and distribution, among other
things, of drugs and drug product candidates. If we do not comply with
applicable requirements, we may be fined, the government may refuse to approve
our marketing applications or allow us to manufacture or market our products,
and we may be criminally prosecuted. We and our manufacturers may also be
subject to regulations under other United States federal, state, and local laws.

UNITED STATES GOVERNMENT REGULATION

In the United States, the FDA regulates drugs under the Federal Food Drug and
Cosmetics Act, or FDCA, and implementing regulations. The process required by
the FDA before our drug candidates may be marketed in the United States
generally involves the following (although the FDA is given wide discretion to
impose different or more stringent requirements on a case-by-case basis):

- - Completion of extensive preclinical laboratory tests, preclinical animal
studies and formulation studies, all performed in accordance with the FDA's
good laboratory practice regulations and other regulations;

- - Submission to the FDA of an IND application which must become effective
before clinical trials may begin;

- - Performance of multiple adequate and well-controlled clinical trials
meeting FDA requirements to establish the safety and efficacy of the
product candidate for each proposed indication;

- - Submission of an NDA to the FDA;

- - Satisfactory completion of an FDA pre-approval inspection of the
manufacturing facilities at which the product candidate is produced, and
potentially other involved facilities as well, to assess compliance with
current good manufacturing practice, or cGMP, regulations and other
applicable regulations;

- - The FDA review and approval of the NDA prior to any commercial marketing,
sale or shipment of the drug.

The testing and approval process requires substantial time, effort and financial
resources, and we cannot be certain that any approvals for our drug candidates
will be granted on a timely basis, if at all.

Preclinical tests may include laboratory evaluation of product chemistry,
formulation and stability, as well as studies to evaluate toxicity and other
effects in animals. The results of preclinical tests, together with
manufacturing information and analytical data, among other information, are
submitted to the FDA as part of an IND application. Subject to certain
exceptions, an IND becomes effective 30 days after receipt by the FDA, unless
the FDA, within the 30-day time period, issues a clinical hold to delay a
proposed clinical investigation due to concerns or questions about the conduct
of the clinical trial, including concerns that human research subjects will be
exposed to unreasonable health risks. In such a case, the IND sponsor and the
FDA must resolve any outstanding concerns before the clinical trial can begin.
Our submission of an IND, or those of our collaboration partners, may not result
in the FDA authorization to commence a clinical trial. A separate submission to
an existing IND must also be made for each successive clinical trial conducted
during product development.

The FDA must also approve changes to an existing IND. Further, an independent
institutional review board, or IRB, for each medical center proposing to conduct
the clinical trial must review and approve the plan for any clinical trial
before it commences at that center and it must monitor the study until
completed. The FDA, the IRB or the sponsor may suspend a clinical trial at any
time on various grounds, including a finding that the subjects or patients are
being exposed to an unacceptable health risk. Clinical testing also must satisfy
extensive Good Clinical Practice requirements and regulations for informed
consent.

CLINICAL TRIALS

For purposes of NDA submission and approval, clinical trials are typically
conducted in the following three sequential phases, which may overlap (although
additional or different trials may be required by the FDA as well):

Phase I clinical trials are initially conducted in a limited population to test
the drug candidate for safety, dose tolerance, absorption, metabolism,
distribution and excretion in healthy humans or, on occasion, in patients, such
as cancer patients. In some cases, particularly in cancer trials, a sponsor may
decide to conduct what is referred to as a "Phase Ib" evaluation, which is a
second safety-focused Phase I clinical trial typically designed to evaluate the
impact of the drug candidate in combination with currently FDA-approved drugs.

Phase II clinical trials are generally conducted in a limited patient population
to identify possible adverse effects and safety risks, to determine the efficacy
of the drug candidate for specific targeted indications and to determine dose
tolerance and optimal dosage. Multiple Phase II clinical trials may be conducted
by the sponsor to obtain information prior to beginning larger and more
expensive Phase III clinical trials. In some cases, a sponsor may decide to
conduct what is referred to as a "Phase IIb" evaluation, which is a second,
confirmatory Phase II clinical trial that could, if positive and accepted by the
FDA, serve as a pivotal clinical trial in the approval of a drug candidate.

Phase III clinical trials are commonly referred to as pivotal trials. When Phase
II clinical trials demonstrate that a dose range of the drug candidate is
effective and has an acceptable safety profile, Phase III clinical trials are
undertaken in large patient populations to further evaluate dosage, to provide
substantial evidence of clinical efficacy and to further test for safety in an
expanded and diverse patient population at multiple, geographically dispersed
clinical trial sites.

In some cases, the FDA may condition continued approval of an NDA on the
sponsor's agreement to conduct additional clinical trials with due diligence. In
other cases, the sponsor and the FDA may agree that additional safety and/or
efficacy data should be provided; however, continued approval of the NDA may not
always depend on timely submission of such information. Such post-approval
studies are typically referred to as Phase IV studies.

NEW DRUG APPLICATION

The results of drug candidate development, preclinical testing and clinical
trials, together with, among other things, detailed information on the
manufacture and composition of the product and

proposed labeling, and the payment of a user fee, are submitted to the FDA as
part of an NDA. The FDA reviews all NDAs submitted before it accepts them for
filing and may request additional information rather than accepting an NDA for
filing. Once an NDA is accepted for filing, the FDA begins an in-depth review of
the application.

During its review of an NDA, the FDA may refer the application to an advisory
committee for review, evaluation and recommendation as to whether the
application should be approved. The FDA may refuse to approve an NDA and issue
a not approvable letter if the applicable regulatory criteria are not satisfied,
or it may require additional clinical or other data, including one or more
additional pivotal Phase III clinical trials. Even if such data are submitted,
the FDA may ultimately decide that the NDA does not satisfy the criteria for
approval. Data from clinical trials are not always conclusive and the FDA may
interpret data differently than we or our collaboration partners interpret data.
If the FDA's evaluations of the NDA and the clinical and manufacturing
procedures and facilities are favorable, the FDA may issue either an approval
letter or an approvable letter, which contains the conditions that must be met
in order to secure final approval of the NDA. If and when those conditions have
been met to the FDA's satisfaction, the FDA will issue an approval letter,
authorizing commercial marketing of the drug for certain indications. The FDA
may withdraw drug approval if ongoing regulatory requirements are not met or if
safety problems occur after the drug reaches the market. In addition, the FDA
may require testing, including Phase IV clinical trials, and surveillance
programs to monitor the effect of approved products that have been
commercialized, and the FDA has the power to prevent or limit further marketing
of a drug based on the results of these post-marketing programs. Drugs may be
marketed only for the FDA-facilities are favorable, the FDA may issue approved
indications and in accordance with the FDA-approved label.

Further, if there are any modifications to the drug, including changes in
indications, other labeling changes, or manufacturing processes or facilities,
we may be required to submit and obtain FDA approval of a new NDA or NDA
supplement, which may require us to develop additional data or conduct
additional preclinical studies and clinical trials.

FAST TRACK DESIGNATION

The FDA's fast track program is intended to facilitate the development and to
expedite the review of drugs that are intended for the treatment of a serious or
life-threatening condition and that demonstrate the potential to address unmet
medical needs. Under the fast track program, applicants may seek traditional
approval for a product based on data demonstrating an effect on a clinically
meaningful endpoint, or approval based on a well-established surrogate endpoint.
The sponsor of a new drug candidate may request the FDA to designate the drug
candidate for a specific indication as a fast track drug at the time of original
submission of its IND, or at any time thereafter prior to receiving marketing
approval of a marketing application. The FDA will determine if the drug
candidate qualifies for fast track designation within 60 days of receipt of the
sponsor's request.

If the FDA grants fast track designation, it may initiate review of sections of
an NDA before the application is complete. This so-called "rolling review" is
available if the applicant provides and the FDA approves a schedule for the
submission of the remaining information and the applicant

has paid applicable user fees. The FDA's PDUFA review clock for both a standard
and priority NDA for a fast track product does not begin until the complete
application is submitted.

Additionally, fast track designation may be withdrawn by the FDA if it believes
that the designation is no longer supported by emerging data, or if the
designated drug development program is no longer being pursued.

In some cases, a fast track designated drug candidate may also qualify for one
or more of the following programs:

Priority Review. As explained above, a drug candidate may be eligible for a
six-month priority review. The FDA assigns priority review status to an
application if the drug candidate provides a significant improvement compared to
marketed drugs in the treatment, diagnosis or prevention of a disease. A fast
track drug would ordinarily meet the FDA's criteria for priority review, but may
also be assigned a standard review. We do not know whether any of our drug
candidates will be assigned priority review status or, if priority review status
is assigned, whether that review or approval will be faster than conventional
FDA procedures, or that the FDA will ultimately approve the drug.

Accelerated Approval. Under the FDA's accelerated approval regulations, the FDA
is authorized to approve drug candidates that have been studied for their safety
and efficacy in treating serious or life- threatening illnesses and that provide
meaningful therapeutic benefit to patients over existing treatments based upon
either a surrogate endpoint that is reasonably likely to predict clinical
benefit or on the basis of an effect on a clinical endpoint other than patient
survival or irreversible morbidity. In clinical trials, surrogate endpoints are
alternative measurements of the symptoms of a disease or condition that are
substituted for measurements of observable clinical symptoms. A drug candidate
approved on this basis is subject to rigorous post-marketing compliance
requirements, including the completion of Phase IV or post-approval clinical
trials to validate the surrogate endpoint or confirm the effect on the clinical
endpoint. Failure to conduct required post-approval studies with due diligence,
or to validate a surrogate endpoint or confirm a clinical benefit during
post-marketing studies, may cause the FDA to seek to withdraw the drug from the
market on an expedited basis. All promotional materials for drug candidates
approved under accelerated regulations are subject to prior review by the FDA.

When appropriate, we and our collaboration partners intend to seek fast track
designation, accelerated approval or priority review for our drug candidates. We
cannot predict whether any of our drug candidates will obtain fast track,
accelerated approval, or priority review designation, or the ultimate impact, if
any, of these expedited review mechanisms on the timing or likelihood of the FDA
approval of any of our drug candidates.

Satisfaction of the FDA regulations and approval requirements or similar
requirements of foreign regulatory agencies typically takes several years, and
the actual time required may vary substantially based upon the type, complexity
and novelty of the product or disease. Typically, if a drug candidate is
intended to treat a chronic disease, as is the case with some of the drug
candidates we are developing, safety and efficacy data must be gathered over an
extended period of time. Government regulation may delay or prevent marketing of
drug candidates for a

considerable period of time and impose costly procedures upon our activities.
The FDA or any other regulatory agency may not grant approvals for changes in
dosage form or new indications for our drug candidates on a timely basis, or at
all. Even if a drug candidate receives regulatory approval, the approval may be
significantly limited to specific disease states, patient populations and
dosages. Further, even after regulatory approval is obtained, later discovery of
previously unknown problems with a drug may result in restrictions on the drug
or even complete withdrawal of the drug from the market. Delays in obtaining, or
failures to obtain, regulatory approvals for any of our drug candidates would
harm our business. In addition, we cannot predict what adverse governmental
regulations may arise from future United States or foreign governmental action.

OTHER REGULATORY REQUIREMENTS

Any drugs manufactured or distributed by us or our collaboration partners
pursuant to future FDA approvals are subject to continuing regulation by the
FDA, including recordkeeping requirements and reporting of adverse experiences
associated with the drug. Drug manufacturers and their subcontractors are
required to register with the FDA and certain state agencies, and are subject to
periodic unannounced inspections by the FDA and certain state agencies for
compliance with ongoing regulatory requirements, including cGMP, which impose
certain procedural and documentation requirements upon us and our third-party
manufacturers. Failure to comply with the statutory and regulatory requirements
can subject a manufacturer to possible legal or regulatory action, such as
warning letters, suspension of manufacturing, sales or use, seizure of product,
injunctive action or possible civil penalties. We cannot be certain that we or
our present or future third-party manufacturers or suppliers will be able to
comply with the cGMP regulations and other ongoing FDA regulatory requirements.
If our present or future third-party manufacturers or suppliers are not able to
comply with these requirements, the FDA may halt our clinical trials, require us
to recall a drug from distribution, or withdraw approval of the NDA for that
drug.

The FDA closely regulates the post-approval marketing and promotion of drugs,
including standards and regulations for direct-to-consumer advertising,
off-label promotion, industry-sponsored scientific and educational activities
and promotional activities involving the Internet. A company can make only those
claims relating to safety and efficacy that are approved by the FDA. Failure to
comply with these requirements can result in adverse publicity, warning and/or
untitled letters, corrective advertising and potential civil and criminal
penalties.

INTELLECTUAL PROPERTY

Our goal is to obtain, maintain and enforce patent protection for our products,
formulations, processes, methods and other proprietary technologies, preserve
our trade secrets, and operate without infringing on the proprietary rights of
other parties, both in the United States and in other countries. Our policy is
to actively seek to obtain, where appropriate, the broadest intellectual
property protection possible for Salicinium and any future product candidates,
proprietary information and proprietary technology through a combination of
contractual arrangements and patents, both in the U.S. and abroad. Currently,
we have entered into a letter of intent for our product candidate, and the
entities from which we have entered into agreement with have either

obtained or applied for patent protection for such product. With respect to the
product, we do not anticipate significant expenses in obtaining and maintain
patent protection on our (and our licensees') behalf, unless and until a claim
or assertion of infringement arises. However, even patent protection may not
always afford us with complete protection against competitors who seek to
circumvent our patents.

RESEARCH AND DEVELOPMENT

Since inception, HSTI has not engaged in any research and development
activities. Our business model is to license technologies developed by other
parties.

COMPETITION

The development and commercialization for new products to treat cancer is highly
competitive, and there will be considerable competition from major
pharmaceutical, biotechnology, and specialty cancer companies. Many of our
competitors have substantially more resources than we do, including both
financial and technical. In addition, many of these companies have more
experience than we do in preclinical and clinical development, manufacturing,
regulatory, and global commercialization. We are also competing with academic
institutions, governmental agencies and private organizations that are
conducting research in the field of cancer. Competition for highly qualified
employees is intense.

DEPENDENCE ON ONE OR A FEW MAJOR CUSTOMERS

HSTI is not dependent on one or a few major customers.

EMPLOYEES

HSTI has four full time employees and two consultants who devote a significant
percentage of their time to the Company. We believe our relationship with our
employees is good.

DESCRIPTION OF PROPERTY OF HSTI

HSTI's executive offices are located at 150 Research Dr., Hampton VA. We
currently share these offices without rent from The Health Network, Inc., of
which Ron Howell is president. The combined office space and warehouse space is
42,600 square feet.

LEGAL PROCEEDINGS OF HSTI

HSTI is not a party to any material legal proceedings and, to the Company's
knowledge, no such proceedings are threatened or contemplated by any party.

INDEMNIFICATION OF HSTI'S DIRECTORS AND OFFICERS

Nevada Revised Statutes ("NRS") Sec. 78.7502 provides, in effect, that any
person made a party to any action by reason of the fact that he is or was a
director, officer, employee or agent of HSTI may and, in certain cases, must be
indemnified by HSTI against, in the case of a non-derivative action, judgments,
fines, amounts paid in settlement and reasonable expenses (including attorneys'
fees) actually and reasonably incurred by him as a result of such action; and in
the case of a derivative action, against amounts paid in settlement and expenses
(including attorneys' fees) actually and reasonably incurred, if in either type
of action he either (1) Is not liable for a breach of his fiduciary duties to
HSTI pursuant to NRS 78.138, or (2) acted in good faith and in a manner he
reasonably believed to be in or not opposed to the best interests of our company
and in, with respect to any criminal, had reasonable cause to believe his
conduct was lawful. This indemnification does not apply, in a derivative
action, to matters as to which it is adjudged that the director, officer,
employee or agent is liable to HSTI, unless upon court order it is determined
that, despite such adjudication of liability, but in view of all the
circumstances of the case, he is fairly and reasonably entitled to
indemnification for expenses.

At present, there is no pending litigation or proceeding involving any director
or officer as to which indemnification is being sought against HSTI, nor are we
aware of any threatened litigation that may result in claims for indemnification
by any director or officer.

CERTAIN RELEATIONSHIPS AND RELATED TRANSACTIONS

Currently HSTI operates out of an office located at 150 Research Dr. in Hampton,
VA. The offices are currently being rented by The Health Network, Inc., whose
president, Ron Howell, is also the president of HSTI. HSTI currently does not
pay rent to the Health Network, Inc.

Mr. Howell also serves as a consultant to HSTI in consideration for a monthly
accrual of $10,000.

ITEM 5.01 CHANGES IN CONTROL OF REGISTRANT

Effective May 5, 2008 and closed on May 9, 2008, the Company entered into a
Reorganization and Stock Purchase Agreement (the "Acquisition") with Health
Source Technologies, Inc. ("HSTI") to acquire 100% of the issued and outstanding
equity of HSTI in exchange for a majority interest in the Company. As a result
of the Acquisition, HSTI is now the majority shareholder of the Corporation,
holding 66,000,000 shares of common stock and 1,000,000 shares of Series A
Preferred Stock. The Series A Preferred Stock is convertible into 405 shares of
common stock per share of Series A Preferred Stock, and has voting,
distribution, and liquidation rights equal to 405 shares of common stock for
every share of Series A Preferred Stock held.

ITEM 5.02 DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.

Pursuant to the terms of the Acquisition, Alan Lew has resigned as the Company's
sole director and officer, and appointed Ron Howell, a designee of HSTI, as the
Company's sole director. In addition, on May 8, 2008, the Board of directors
appointed Ron Howell as Chief Executive Officer and Chairman, and Wesley D. Tate
as Chief Financial Officer and Secretary.

RONALD R. HOWELL, CHIEF EXECUTIVE OFFICER AND CHAIRMAN: Mr. Howell has over 30
years of diversified leadership experience. He has distinguished himself in
various businesses and held executive positions in various industries including
real estate, distribution, national and international sales, wholesale and
retail marketing, financial service. Mr. Howell serves as the CEO and President
of The Health Network, Inc. and has served in that capacity for over 5 years.
The Health Network, Inc. is a direct sales and marketing company in the
nutraceutical industry.

Holding a Bachelor's Degree in Management from the University of Maryland and an
MBA from the Sellinger School of Business and Management at Loyola College, Mr.
Howell has also taught as an Adjunct Professor at Loyola College in Baltimore,
Maryland. Ron also served his country as a United States Marine.

WESLEY D. TATE, CHIEF FINANCIAL OFFICER AND SECRETARY: Prior to joining the
Company Mr. Tate served as Executive Vice President and Chief Operating Officer
for InnerLight Inc. in Provo Utah for over five years. Before that, he was
Assistant Chief Financial Officer for Beverly Sassoon and Co. in Boca Raton,
Florida. Wes has spent almost 15 years in the Direct Sales Industry working
with a number of different companies. He also has experience outside the direct
sales industry, having worked with a number of fortune 500 companies.

Mr. Tate received his Bachelor of Science degree from the University of
Tennessee, Knoxville, with majors in finance and psychology and his Masters of
Business Administration from the University of Tennessee, Knoxville, with
concentrations in finance and management. Wes served his country in the United
States Army.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(a) Financial Statements

Set forth below.

Exhibit Description
- ------- -----------

2.4 Reorganization and Stock Purchase Agreement between NT Holding
Corp. and Health Source Technologies, Inc.*

2.5 Assignment and Assumption Agreement between NT Holding Corp. and
Rider Point International.*

10.1 Letter of Intent between Health Source Technologies, Inc. and
Joe Brown dated December 27, 2007.*

* Included in the Company's form 8-K filed May 15, 2008, and incorporated herein
by this reference

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

Dated: May 19, 2008 NT HOLDING CORP.
(Registrant)

By: /s/ Ron Howell
------------------
Ron Howell
Chief Executive Officer

HEALTH SOURCE TECHNOLOGIES, INC.
(A DEVELOPMENT STAGE COMPANY)

FINANCIAL STATEMENTS

TABLE OF CONTENTS

Report of Independent Registered Public Accounting Firm. .........F-2

Consolidated Balance Sheets as of December 31, 2007. ............F-3

Consolidated Statements of Operations for the period
from August 6, 2007 (Inception) through December 31, 2007. ........F-4

Consolidated Statements of Changes in Stockholders' Equity
for the period from August 6, 2007 (Inception)
through December 31, 2007. ........................................F-5

Consolidated Statements of Cash Flows for the period
from August 6, 2007 (Inception) through December 31, 2007. .......F-6

Notes to Financial Statements. .............................F-7 to F-9

F-1

Board of Directors
Health Source Technologies, Inc.
Hampton, Virginia

REPORT OF INDEPENDENT REGISTERED ACCOUNTING FIRM

We have audited the accompanying balance sheet of Health Source Technologies,
Inc. (a Development Stage Company) as of December 31, 2007 and the statements of
operations, stockholders' equity and cash flows for the period from the date of
inception (August 6, 2007) through December 31, 2007. These consolidated
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these consolidated financial
statements based on our audit.

We conducted our audit in accordance with auditing standards of the Public
Company Accounting Oversight Board ("PCAOB"). Those standards require that we
plan and perform an audit to obtain reasonable assurance whether the financial
statements are free of material misstatement. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over
financial reporting. Our audit included consideration of internal control over
financial reporting as a basis for designing audit procedures that are
appropriate in the circumstances, but not for the purpose of expressing an
opinion on the effectiveness of the company's internal control over financial
reporting. Accordingly, we express no such opinion. An audit also includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting
principles used, significant estimates made by management and evaluating the
overall financial statement presentation. We believe that our audits provide a
reasonable basis for our opinion.

In our opinion, these financial statements referred to above present fairly, in
all material aspects, the consolidated financial position of the Company as of
December 31, 2007, and the results of its operations and cash flows for the
period from the date of inception (August 6, 2007) through December 31, 2007,
in conformity with accounting principles generally accepted in the United States
of America.

The accompanying financial statements have been prepared assuming that the
Company will continue as a going concern. The Company does not have the
necessary working capital to service its debt and for its planned activity,
which raises substantial doubt about its ability to continue as a going concern.
Management's plans in regard to these matters are described in the footnotes to
the financial statements. These financial statements do not include any
adjustments that might result from the outcome of this uncertainty.

/s/ Madsen & Associates CPA's, Inc.
- -----------------------------------
Madsen & Associates CPA's, Inc.
May 7, 2008
Salt Lake City, Utah

F-2

HEALTH SOURCE TECHNOLOGIES, INC.
(A DEVELOPMENT STAGE COMPANY)

Consolidated Balance Sheets

DECEMBER 31, 2007
ASSETS
Cash $ 985
-------------------

TOTAL ASSETS $ 985
===================

LIABILITIES AND STOCKHOLDERS' EQUITY

LIABILITES:
Accounts payable 1,340
Accounts payable - related parties 60,882
-------------------
TOTAL CURRENT LIABILITES 62,222

STOCKHOLDERS' EQUITY:
Common stock, no par value;
$1.00 stated value, 1,500 shares
authorized 1,500 issued and
outstanding 1,500
Additional paid in capital -
Deficit accumulated during the exploration stage (62,737)
-------------------

TOTAL STOCKHOLDERS' EQUITY (61,237)
-------------------

TOTAL LIABILITIES AND
STOCKHOLDERS' EQUITY $ 985
===================

The accompanying notes are an integral part of the financial statements

F-3

HEALTH SOURCE TECHNOLOGIES, INC.
(A DEVELOPMENT STAGE COMPANY)

Statement of Operations

FROM AUGUST 6, 2007
(DATE OF INCEPTION )
TO DECEMBER 31, 2007
-----------------------

REVENUE: $ -
-----------------------
TOTAL REVENUE -

OPERATING EXPENSES:
Salaries 30,000
Consulting 30,000
Other general & administrative 2,737
-----------------------

TOTAL OPERATING EXPENSES 62,737

NET LOSS $ (62,737)
=======================

WEIGHTED AVERAGE SHARES
COMMON STOCK OUTSTANDING 1,500
=======================

NET LOSS PER SHARE (BASIC AND FULLY DILUTIVE) $ (41.82)
=======================

The accompanying notes are an integral part of the financial statements

F-4

HEALTH SOURCE TECHNOLOGIES, INC.
(A DEVELOPMENT STAGE COMPANY)

Statement of Changes in Stockholder Equity
From August 6, 2007 (inception) to December 31, 2007

Common Stock
100,000,000 shares authorized
--------------------------------

Par Value Deficit accumulated
No Par Value Additional during the
Shares $1.00 Stated Paid-In development
Issued Value Capital stage Total
-------------- ---------------- ----------- --------------------- ---------

BALANCE- August 6, 2007 (inception) - $ - $ - $ - $ -

Issuance of common stock
for cash - October 2, 2007 1,500 1,500 1,500

Net (loss) for period ended June 30, 2007 (62,737) (62,737)
-------------- ---------------- ----------- --------------------- ---------

BALANCE- December 31, 2007 1,500 $ 1,500 $ - $ (62,737) $(61,237)
============== ================ =========== ===================== =========

<FN>

The accompanying notes are an integral part of the financial statements

F-5

HEALTH SOURCE TECHNOLOGIES, INC.
(A DEVELOPMENT STAGE COMPANY)

Statement of Cash Flows

FROM AUGUST 6, 2007
(DATE OF INCEPTION )
TO DECEMBER 31, 2007
----------------------
CASH FLOWS USED IN OPERATING ACTIVITIES:

NET LOSS $ (62,737)

ADJUSTMENTS TO RECONCILE NET (LOSS) TO NET
CASH PROVIDED BY OPERATING ACTIVITES:

CHANGES IN OPERATING ASSETS AND LIABILITES

Increase in accounts payable 62,222
----------------------

NET CASH USED IN OPERATING ACTIVITIES (515)
----------------------

CASH FLOWS FROM FINANCING ACTIVITIES:

Issuance of common stock for cash 1,500
----------------------

NET CASH PROVIDED BY FINANCING ACTIVITIES 1,500

NET INCREASE (DECREASE) IN CASH 985

CASH AT BEGINNING OF YEAR -
----------------------
-
CASH AT END OF YEAR $ 985
======================

The accompanying notes are an integral part of the financial statements

F-6

HEALTH SOURCE TECHNOLOGIES, INC.
(A DEVELOPMENT STAGE COMPANY)

Notes to the Financial Statements
December 31, 2007

NOTE 1 - NATURE AND PURPOSE OF BUSINESS

Health Source Technologies, Inc. (the Company) was incorporated under the laws
of the state of Nevada on August 6, 2007. The Company is currently headquartered
in Hampton, Virginia. The Company is a biopharmaceutical company in the
development stage with a focus on acquiring and developing products for the
treatment of cancer.

NOTE 2 - NATURE OF SIGNIFICANT ACCOUNTING POLICIES

CASH AND CASH EQUIVALENTS
- ----------------------------

The Company considers all highly liquid debt instruments purchased with maturity
of three months or less to be cash equivalents.

REVENUE RECOGNITION
- --------------------

The Company considers revenue to be recognized at the time the service is
performed.

USE OF ESTIMATES
- ------------------

The preparation of the Company's financial statements requires management to
make estimates and assumptions that affect the amounts reported in the financial
statements and accompanying notes. Actual results could differ from these
estimates.

FAIR VALUE OF FINANCIAL INSTRUMENTS
- ---------------------------------------

The Company's short-term financial instruments consist of cash and cash
equivalents and accounts payable. The carrying amounts of these financial
instruments approximate fair value because of their short-term maturities.
Financial instruments that potentially subject the Company to a concentration of
credit risk consist principally of cash. During the year the Company did not
maintain cash deposits at financial institution in excess of the $100,000 limit
covered by the Federal Deposit Insurance Corporation. The Company does not hold
or issue financial instruments for trading purposes nor does it hold or issue
interest rate or leveraged derivative financial instruments.

EARNINGS PER SHARE
- --------------------

Basic Earnings per Share ("EPS") is computed by dividing net income available to
common stockholders by the weighted average number of common stock shares
outstanding during the year. Diluted EPS is computed by dividing net income
available to common stockholders by the weighted-average number of common stock
shares outstanding during the year plus potential

F-7

HEALTH SOURCE TECHNOLOGIES, INC.
(A DEVELOPMENT STAGE COMPANY)

Notes to the Financial Statements
December 31, 2007

dilutive instruments such as stock options and warrant. The effect of stock
options on diluted EPS is determined through the application of the treasury
stock method, whereby proceeds received by the Company based on assumed
exercises are hypothetically used to repurchase the Company's common stock at
the average market price during the period. Loss per share is unchanged on a
diluted basis since the assumed exercise of common stock equivalents would have
an anti-dilutive effect.

INCOME TAXES:

The Company uses the asset and liability method of accounting for income taxes
as required by SFAS No. 109 "Accounting for Income Taxes". SFAS 109 requires
the recognition of deferred tax assets and liabilities for the expected future
tax consequences of temporary differences between the carrying amounts and the
tax basis of certain assets and liabilities. Deferred income tax assets and
liabilities are computed annually for the difference between the financial
statement and tax bases of assets and liabilities that will result in taxable or
deductible amounts in the future, based on enacted tax laws and rates applicable
to the periods in which the differences are expected to affect taxable income.
Valuation allowances are established when necessary to reduce deferred tax
assets to the amount expected to be realized. Income tax expense is the tax
payable or refundable for the period, plus or minus the change during the period
in deferred tax assets and liabilities.

Deferred income taxes may arise from temporary differences resulting from income
and expanse items reported for financial accounting and tax purposes in
different periods. Deferred taxes are
classified as current or non-current, depending on the classification of the
assets and liabilities to which they relate. Deferred taxes arising from
temporary differences that are not related to an
asset or liability are classified as current or non-current depending on the
periods in which the temporary differences are expected to reverse. The Company
had no significant deferred tax items arise during any of the periods presented.

CONCENTRATION OF CREDIT RISK:

The Company does not have any concentration of related financial credit risk.

RECENT ACCOUNTING PRONOUNCEMENTS:

The Company does not expect that the adoption of other recent accounting
pronouncements will have a material impact to its financial statements.

NOTE 3 - ACCOUNTS PAYABLE - RELATED PARTIES

The Company has accrued amounts as salaries and consulting expense payable to
stockholders for services rendered to the Company during the period ended
December 31, 2007.

F-8

HEALTH SOURCE TECHNOLOGIES, INC.
(A DEVELOPMENT STAGE COMPANY)

Notes to the Financial Statements
December 31, 2007

NOTE 4 - COMMON STOCK

The Company issued 1,500 shares of its common stock in October of 2007 for cash
in the amount of $1,500.

NOTE 5 - GOING CONCERN

The accompanying financial statements have been prepared assuming the Company
will continue as a going concern. As shown in the accompanying financial
statements, the Company has no sales and has incurred a net loss of $ 62,737
since inception. The future of the Company is dependent upon its ability to
obtain financing and upon future profitable operations from the development of
its business. Management has plans to seek additional capital through a private
placement and public offering of its common stock. The financial statements do
not include any adjustments relating to the recoverability and classifications
of recorded assets, or the amounts of and the classification of liabilities that
might be necessary in the event the Company cannot continue in existence.

F-9